Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991602 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL12902066 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL4985877 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL3264264 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL12646290 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL3176573 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL3172961 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL3167448 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL14361057 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL4985872 | 0.91 | TACR1 (1.00) | TACR1CYP3A4CYP2C8CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036135-A1 | Process for Making Hydroisoindoline Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7544815-B2 | Process for making hydroisoindoline tachykinin receptor antagonists | MERCK & CO, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036135-A1 | Process for Making Hydroisoindoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CYP3A4 2681/4885CYP2C8 3095/4885 |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CYP3A4 2681/4885CYP2C8 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.